Patents by Inventor Heike Schauerte
Heike Schauerte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150011576Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.Type: ApplicationFiled: September 22, 2014Publication date: January 8, 2015Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
-
Patent number: 8841315Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.Type: GrantFiled: August 12, 2013Date of Patent: September 23, 2014Assignee: AstraZeneca ABInventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
-
Publication number: 20130338147Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.Type: ApplicationFiled: August 12, 2013Publication date: December 19, 2013Applicant: Ingenium Pharmaceuticals GmbHInventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
-
Publication number: 20130331407Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.Type: ApplicationFiled: August 12, 2013Publication date: December 12, 2013Applicant: Ingenium Pharmaceuticals GmbHInventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
-
Patent number: 8507511Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).Type: GrantFiled: April 24, 2008Date of Patent: August 13, 2013Assignee: Ingenium Pharmaceuticals GmbHInventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
-
Patent number: 8507498Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.Type: GrantFiled: April 24, 2008Date of Patent: August 13, 2013Assignee: Ingenium Pharmaceuticals GmbHInventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
-
Patent number: 8436007Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.Type: GrantFiled: April 24, 2008Date of Patent: May 7, 2013Assignee: Ingenium Pharmaceuticals GmbHInventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller
-
Patent number: 8389521Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).Type: GrantFiled: April 24, 2008Date of Patent: March 5, 2013Assignee: Ingenium Pharmaceuticals GmbHInventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
-
Publication number: 20110306602Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.Type: ApplicationFiled: April 24, 2008Publication date: December 15, 2011Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Lutz Zeitlmann, Anke Mueller, Martin Augustin, Michael A. Pleiss, Gabriele Stumm, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
-
Publication number: 20100184780Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).Type: ApplicationFiled: April 24, 2008Publication date: July 22, 2010Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
-
Publication number: 20100184789Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.Type: ApplicationFiled: April 24, 2008Publication date: July 22, 2010Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller
-
Publication number: 20100168144Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).Type: ApplicationFiled: April 24, 2008Publication date: July 1, 2010Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
-
Publication number: 20090221581Abstract: The invention relates to methods of treating any type of pain comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.Type: ApplicationFiled: May 24, 2006Publication date: September 3, 2009Inventors: Philipp Wabnitz, Heike Schauerte, Gabriele Stumm, Joachim Freitag
-
Publication number: 20080275063Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceutical compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.Type: ApplicationFiled: April 24, 2007Publication date: November 6, 2008Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
-
Patent number: 7435868Abstract: The invention relates to the identification and use of the DAF-2/IR responsive sod-3 promoter. Transgenic C. elegans containing sod-3 reporter gene constructs are described which are useful for, among other things, the identification of genes or compounds capable of modulating the DAF-2/IR-akt pathway. Conditions are disclosed that increase or decrease the reporter activity, demonstrating the presence of either activators or inhibitors of the DAF-2/IR pathway.Type: GrantFiled: January 28, 2004Date of Patent: October 14, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventors: Edmund Hoppe, Ulrike Siebers, Heike Schauerte, Jonathan Rothblatt
-
Publication number: 20050020527Abstract: The present invention relates to a non-human vertebrate animal model displaying an alteration in fat metabolism or in the sensitivity towards leptin or insulin, which model bears a mutation in the gene encoding the spinster like 1 protein (Spinl1). The invention also relates to mutant Spinl1 proteins and nucleic acid sequences encoding these proteins. Furthermore, the invention relates to the use of the non-human vertebrate animal model for the identification of diagnostic markers, or as a model for studying the molecular and physiological mechanisms associated with an alteration in fat metabolism or an alteration in the sensitivity towards leptin or insulin, or for the identification and testing of agents useful in the prevention, amelioration, or treatment of the above conditions. Agents, pharmaceutical compositions, and methods for treating the above conditions are likewise described, as are methods for identifying said agents.Type: ApplicationFiled: April 5, 2004Publication date: January 27, 2005Inventors: Thomas Peters, Volker Schluter, Johannes Grosse, Heike Schauerte, Andreas Marquardt
-
Publication number: 20040259117Abstract: The invention relates to the identification and use of the DAF-2/IR responsive sod-3 promoter. Transgenic C. elegans containing sod-3 reporter gene constructs are described which are useful for, among other things, the identification of genes or compounds capable of modulating the DAF-2/IR-akt pathway. Conditions are disclosed that increase or decrease the reporter activity, demonstrating the presence of either activators or inhibitors of the DAF-2/IR pathway.Type: ApplicationFiled: January 28, 2004Publication date: December 23, 2004Applicant: Aventis Pharma Deutschland GmbHInventors: Edmund Hoppe, Ulrike Siebers, Heike Schauerte, Jonathan Rothblatt